Pfizer, Inc. · NYSE:PFE
Pfizer — Investor Day (September 2020)
26 slides from Pfizer's investor day presentation, Sep 14, 2020
Slide 1: Internal Medicine
Internal Medicine Pfizer Confidential 1
Slide 2: Forward-Looking Statements and Other Notices
Forward-Looking Statements and Other Notices Our discussions during Pfizer’s Investor Day include forward-looking statements about our anticipated future operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates,
Slide 3: Leadership Team Brings 75+ Collective Years of Cardiometabolic and Internal Medicine Expertise
Leadership Team Brings 75+ Collective Years of Cardiometabolic and Internal Medicine Expertise Mike Gladstone Jim Rusnak Morris Birnbaum Global President, Chief Development Officer, Chief Scientific Officer, Internal Medicine Internal Medicine Internal Medicine 3
Slide 4: We Develop Breakthroughs that Impact Millions
We Develop Breakthroughs that Impact Millions 59M reached We prevent and treat the most prevalent health challenges facing society in 2019 Industry-leading Strong internal Heritage and expertise in footprint with cardiology pipeline enhanced via cardiometabolic conditions and primary care strategic
Slide 5: Our R&D Strategy: Address the Burden of the Dysmetabolic State
Our R&D Strategy: Address the Burden of the Dysmetabolic State, Which Contributes to Multiple Chronic Diseases NASH increases risk of serious outcomes (liver failure, CV events) – no approved therapies NASH Six potential first-in-class metabolic MOAs in our discovery and development portfolio Type 2
Slide 6: Robust Early and Mid-Stage Pipeline with Multiple MOAs Targeting Cardiometabolic Conditions
Robust Early and Mid-Stage Pipeline with Multiple MOAs Targeting Cardiometabolic Conditions NASH Cardiovascular T2D/Obesity Cachexia Additional In line Phase 3 / Tanezumab Registration DGAT2 Inhibitor Oral GLP-1RA Vupanorsen ervogastat1 danuglipron3 KHK Inhibitor KHK Inhibitor PF-06835919 PF-0683591
Slide 7: Vupanorsen (antisense oligonucleotide)
Vupanorsen (antisense oligonucleotide) Reducing significant residual CV risk with a genetically- validated, potential first-in- class treatment 7
Slide 8: Cardiovascular Disease is Still the Leading Cause of Death, Driven by Residual Cardiovascular Risk
Cardiovascular Disease is Still the Leading Cause of Death, Driven by Residual Cardiovascular Risk – Despite LDL-C Lowering • Cardiovascular disease (CVD) Substantial Residual CV Risk Remains Despite LDL-C Lowering accounts for 1 of every 3 deaths in the US1 FOURIER3 Median LDL-C with evolocumab = 3
Slide 9: Vupanorsen May Provide Potential First-in-Class Treatment for CV Risk Reduction Through ANGPTL3
add source Vupanorsen May Provide a Potential for third bullet First-in-Class Treatment for CV Risk Reduction Through Reducing ANGPTL3, a Genetically Validated Risk Factor ApoB-containing lipoprotein turnover in the circulation is governed by ANGPTL3 ANGPTL3 Liver Hepatic secretion LPL EL Lipolysis
Slide 10: In a Phase Study, Vupanorsen Demonstrated Robust Reductions in Triglycerides and Non-HDL Cholesterol
In a Phase 1 Study, Vupanorsen Demonstrated Robust Reductions in Triglycerides and Non-HDL Cholesterol, Important CVD Risk Factors Reduction in non-HDL-C is strongly associated with lower risk of major vascular events 1.0 20 20 (% change from baseline) (% change from baseline) 0 0.9 Relative Risk 0
Slide 11: Vupanorsen Development Program is Intended to Support Multiple Indications
Vupanorsen Development Program is Intended to Support Multiple Indications and Advance the Science on ANGPTL3 2020 2021 2022 2023 2024 2025 2026 2027 2028 Phase 3 vs SHTG Placebo (vupanorsen) Phase 3 vs Vascepa Phase 2b CVRR Phase 3 CVOT (vupanorsen) Timings are approximate and subject to change. Po
Slide 12: Clesacostat / Ervogastat (ACC / DGAT2 Inhibitors)
Clesacostat / Ervogastat (ACC / DGAT2 Inhibitors) Leveraging our deep metabolic knowledge to develop breakthrough medicines for NASH 12
Slide 13: Impact of NASH is Growing and There are Currently No FDA- or EMA-Approved Therapies
Driven by Increases in Obesity, the Impact of Nonalcoholic Steatohepatitis (NASH) is Growing and There are Currently No FDA- or EMA-Approved Therapies Challenging to Prevalence Expected Health Consequences Diagnose and Treat to Grow are Significant 10 to 17x increase in liver-related Non-specific sy
Slide 14: Pfizer's Strategy is to Address the Underlying Metabolic Engine that Drives Disease Pathogenesis
Pfizer’s Strategy is to Address the Underlying Metabolic Engine that Drives Disease Pathogenesis Hepatocellular Disordered Inflammation and Progressive fibrosis Carcinoma metabolism cellular injury Normal Steatosis NASH with or Cirrhosis liver without fibrosis Liver Failure Anti-steatotic Anti-steat
Slide 15: Complementary Mechanisms of Action for DGAT2 and ACC Inhibitors
Complementary Mechanisms of Action for DGAT2 and ACC Inhibitors Offer Potential for Best-in-Class Therapy Inflammation TG ervogastat DGAT2 ? DAG Adaptive Decrease Oxidation Fatty Acid CO2 Synthesis SREBP Signaling Adaptive Malonyl CoA Increase clesacostat ACC Fibrosis ? Acetyl CoA SREBP = sterol reg
Slide 16: DGAT2 Inhibition with Ervogastat Demonstrated Reductions in Steatosis and Serum Triglyceride
DGAT2 Inhibition with Ervogastat (PF-06865571) Demonstrated Reductions in Steatosis and Serum Triglyceride 1 2 Phase Weeks Dosed twice daily PBO, 50, 300 mg (N = 48) (% relative change from baseline) 0 Liver Fat Content -10 21 – 26% -20 decrease in serum TG -30 -40 -50 Placebo 50 mg Q12 300 mg Q12 S
Slide 17: ACC Inhibition with Clesacostat Demonstrated Statistically Significant Reductions in Steatosis and ALT
ACC Inhibition with Clesacostat (PF-05221304) Demonstrated Statistically Significant Reductions in Steatosis and ALT, but Increases in Serum Triglycerides 2 16 Phase Weeks Dosed once daily PBO, 2,10, 25 & 50 mg (N = 305) 0 0 120 (% relative change from baseline) -10 100 (% change from baseline) (% c
Slide 18: Clesacostat / Ervogastat Maintains Liver Fat Lowering and Mitigates Serum Triglyceride Increases
Clesacostat / Ervogastat Maintains Statistically Significant Liver Fat Lowering and Mitigates Serum Triglyceride Increases of ACCi 2a 6 Phase Weeks Dosed twice daily PBO, ACCi 15 mg; DGAT2i 300 mg; ACCi + DGAT2i (N = 99) 10 40 60 (% relative change from baseline) >50% Reduction in Liver Fat % of Pat
Slide 19: We are Positioned to Advance Potential First- or Best-in-Class NASH Compounds
We are Positioned to Advance Potential First- or Best-in-Class NASH Compounds 2020 2021 2022 2023 2024 2025 2026 2027 DGAT2i Phase 2b (ervogastat) Phase 3 ACCi/DGAT2i (clesacostat/ Phase 2b ervogastat) KHKi Phase 2a Phase 2b (PF-06835919) Oral GLP-1RA Phase 2b (danuglipron) Timings are approximate a
Slide 20: Danuglipron (GLP-1RA)
Danuglipron (GLP-1RA) Addressing a metabolic epidemic with the potential first small molecule oral GLP- 1RA for both T2D and Obesity 20
Slide 21: Oral GLP-1RA Has the Potential to Address Treatment Gaps in Type 2 Diabetes and Obesity
Oral GLP-1RA Has the Potential to Address Treatment Gaps in Two Global Epidemics: Type 2 Diabetes and Obesity Rising Rates of Diabetes and Obesity Injectable GLP-1RAs Are Underutilized – Carry Significant Health Potential for Oral GLP-1RA to Address This Gap6,7 Consequences Diabetes US $ Share While
Slide 22: Innovative Research Led to Discovery of Breakthrough Small Molecule GLP-1RA
Innovative Research Led to Discovery of Breakthrough Small Molecule GLP-1RA That Differentiates from Injectable and Oral Peptide Class Clinical Candidate Potential to Offer a Uniquely Differentiated Profile • Expected to deliver potent effects on blood sugar and weight loss • Expected to have safety
Slide 23: Danuglipron Demonstrated Robust Reduction in Fasting Glucose, HbA1c and Body Weight at 28 Days
Danuglipron Demonstrated Robust Reduction in Fasting Glucose, HbA1c and Body Weight at 28 Days in Type 2 Diabetes 1 4 Subjects with T2D on Stable Metformin Background Baseline: BMI 32.9 kg/m2 Phase Weeks Dosed twice daily Baseline: HbA1c: 8.3% PBO, 15 mg, 70 mg, 120 mg* 0 0 0 -10 -1 Fasting Plasma G
Slide 24: We Have the Potential to Dramatically Improve Treatment of Diabetes and Obesity with Danuglipron
We Have the Potential to Dramatically Improve Treatment of Diabetes and Obesity with Our Small Molecule Oral GLP-1RA, Danuglipron 2020 2021 2022 2023 2024 2025 2026 T2D Phase 2 Phase 3 (danuglipron) Obesity Phase 2 Phase 3 (danuglipron) NASH Phase 2b (danuglipron) Timings are approximate and subject
Slide 25: Internal Medicine's Innovative Pipeline Positions Us to Address Significant Needs of Patients
Internal Medicine’s Innovative Pipeline Positions Us to Address Significant Needs of Patients with Cardiometabolic Diseases Our aspiration is to reduce the morbidity and mortality burden of these highly prevalent cardiometabolic diseases NASH: 18 million US patients, ~30% have F2/F31,2 NASH Type 2 C
Slide 26: Thank You
Thank You Pfizer Confidential 26